For over a decade, Valcyte has been prescribed to help prevent CMV disease in high-risk (D+/R-)* transplant patients1,2

Valcyte is a CMV nucleoside analogue DNA polymerase inhibitor indicated for the
prevention of CMV disease in:1

  • Adult kidney, heart, and kidney-pancreas patients who are at high risk (D+/R-)*1
  • Pediatric kidney transplant patients (4 months to 16 years) who are at high risk (D+/R-)*1
  • Pediatric heart transplant patients (1 month to 16 years) who are at high risk (D+/R-)*1

Valcyte is available in two formulations1

Valcyte tablets are available for:

  • Adult kidney, heart, and
    kidney-pancreas transplant patients1
  • Pediatric kidney transplant patients (4 months to 16 years)1
  • Pediatric heart transplant patients (1 month to 16 years)1

Not actual size and may not represent exact color.

Valcyte oral solution (OS)
is available for pediatric kidney transplant patients (4 months to 16 years) and pediatric heart transplant patients (1 month to 16 years)1

Not actual size.

Important Valcyte dosing information1

  • Adult patients should use Valcyte tablets, not Valcyte for oral solution
  • Valcyte should be taken with food
  • The bioavailability of ganciclovir from Valcyte is significantly higher than from ganciclovir capsules. Therefore, Valcyte tablets cannot be substituted for ganciclovir capsules on a one-to-one basis
  • Valcyte tablets should not be broken or crushed
  • Valcyte for oral solution must be prepared by the pharmacist prior to dispensing to the patient